Application of triterpenoid compound in preparation of hypoglycemic drug or functional food
By using triterpene obtusalin to promote glucose uptake and inhibit α-glucosidase activity, the problem of single target regulating blood sugar in the prior art was solved, and effective blood sugar-lowering effect on type 1 and type 2 diabetes is achieved. It is suitable for Various diabetes patients.
Patent Information
- Application Number
- CN202211478803.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2022-11-23
- Publication Date
- 2024-11-19
- Estimated Expiration
- 2042-11-23
AI Technical Summary
In the prior art, the therapeutic drugs for diabetes are mostly concentrated on a single target, making it difficult to effectively regulate blood sugar levels in multiple aspects, and there is an urgent need for undiagnosed patients with type 2 diabetes.
The triterpene compound obtusalin is used to prepare different dosage forms of drugs by promoting the uptake of glucose by adipocytes and inhibiting the activity of α-glucosidase as an ingredient in multi-target blood sugar-lowering drugs or functional foods, and combine pharmaceutical excipients.
It significantly reduces blood sugar levels, has a dual effect of lowering blood sugar, is effective for both type 1 and type 2 diabetes, and is highly safe, suitable for a wide range of diabetics.
Smart Images

Figure CN115737653B_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the application field of medicine or health care products, and specifically to the application of a triterpenoid compound in the preparation of a medicine or functional food, and especially to the application of a triterpenoid compound in the preparation of a medicine or functional food for lowering blood sugar, preventing and / or treating diabetes. Background Art
[0002] Diabetes is a metabolic disease that causes abnormal tissue and organ function and structure due to excessively high blood sugar levels. Its pathogenesis is that various pathogenic factors act on the body to cause pancreatic islet dysfunction and insulin resistance, thereby causing imbalances in sugar, protein, fat, water and electrolytes. In clinical medicine, it mainly manifests itself in patients with polyuria, polyphagia, polydipsia, and weight loss. According to the latest data released by the International Diabetes Federation (IDF) in 2021, as of 2021, the number of adult diabetes patients in the world has reached 537 million, about one-tenth of adults are affected, and an estimated 44.7% of adult diabetes patients (240 million people) have not been diagnosed. Diabetes has become the third most serious chronic non-communicable disease threatening human health after tumors and cardiovascular diseases, and is an increasingly serious public health problem. The persistent high blood sugar and long-term metabolic disorders of diabetes can lead to damage to tissues and organs throughout the body, especially the cardiovascular and cerebrovascular, eye, kidney and nervous systems, as well as their dysfunction and failure, and are high-risk factors for major diseases such as cardiovascular and cerebrovascular diseases, tumors and new crowns. The research and development of new blood sugar-lowering drugs or functional foods remains a research hotspot in the field of anti-diabetic treatment.
[0003] α-Glucosidase belongs to the class of oligosaccharide hydrolases. Its inhibitors competitively inhibit the action of glycosidases on the villi of the small intestinal epithelium to reduce the degradation of sugars, delay the digestion and absorption of sugars, and thus effectively reduce the peak blood sugar concentration after meals in diabetics, achieving the purpose of controlling blood sugar. α-Glucosidase inhibitors (such as acarbose, etc.) are a class of oral hypoglycemic drugs widely used in clinical practice, and can be widely used for blood sugar control in patients with type 1 and type 2 diabetes.
[0004] Insulin acts on peripheral tissues (such as adipose tissue, skeletal muscle, etc.), activates their intracellular signal transduction pathways, and then initiates glucose uptake. This series of reactions plays a key role in the body's regulation of glucose levels. Different insulin stimulation concentrations are linearly related to the amount of glucose uptake by adipose tissue / skeletal muscle caused by insulin stimulation within the effective range. By detecting the amount of glucose uptake by adipocytes, their sensitivity to insulin and their hypoglycemic activity can be reflected.
[0005] α-Glucosidase inhibitors and insulin sensitizers are two mature classes of drugs in clinical anti-diabetic treatment. Diabetes is a complex disease with multiple targets and multiple organs and complicated etiology and pathology. Therefore, the market has a more urgent demand for new hypoglycemic drugs with multiple targets. Summary of the invention
[0006] In view of the problems of the prior art, the object of the present invention is to provide a novel hypoglycemic drug with multiple targets, and in particular to provide an application of a triterpenoid compound in the preparation of a drug or functional food for hypoglycemic, preventing and / or treating diabetes.
[0007] In order to achieve the purpose of the invention, the present invention adopts the following technical solutions:
[0008] In the first aspect, the present invention provides the use of a triterpenoid compound represented by formula I or a pharmaceutically acceptable salt, ester, or solvate thereof in the preparation of a drug or functional food for lowering blood sugar, preventing and / or treating diabetes:
[0009]
[0010] Preferably, the blood sugar lowering is to reduce high blood sugar in type 1 diabetes or type 2 diabetes.
[0011] Preferably, the medicine or functional food has the effects of promoting cellular glucose uptake and inhibiting α-glucosidase activity.
[0012] The English name of Formula I is obtusalin, which can be isolated from the Rubiaceae plant yellow cottonwood and has high safety.
[0013] Preferably, the medicine or functional food further comprises pharmaceutically or food acceptable excipients, wherein the excipients include any one or a combination of at least two of carriers, diluents, excipients, fillers, binders, wetting agents, disintegrants, emulsifiers, cosolvents, solubilizers, osmotic pressure regulators, surfactants, coating materials, colorants, pH regulators, antioxidants, antibacterial agents or buffers;
[0014] Preferably, the pharmaceutical dosage form is a tablet, capsule, injection, granule or oral liquid;
[0015] Preferably, the daily dosage of the triterpenoid compound is 0.01-100 mg / kg calculated based on body weight.
[0016] The present invention unexpectedly discovered that the triterpenoid compound shown in Formula I or its pharmaceutically acceptable salt, ester, solvate can promote the uptake of glucose by fat cells and inhibit the activity of α-glucosidase, and can be used for the prevention and treatment of hypoglycemia or diabetes. The inventors conducted experimental studies on the glucose uptake by fat cells and the activity of α-glucosidase inhibitors and found that the compound obtusalin has the activity of significantly promoting the uptake of glucose by fat cells (the glucose uptake rate at a concentration of 20ug / ml is 52.16±1.09% (24 hours), 91.58±0.13%; the blank control is 44.60±0.46% (24 hours), 79.62±0.026% (48 hours); the positive drug berberine is 63.31±0.82% (24 hours), 95.00±0.26% (48 hours)); at the same time, the compound also has the activity of inhibiting α-glucosidase, and its IC 50 The value is 68.80±16.27μg / ml, which can play a good role in the treatment and prevention of type 1 and type 2 diabetes.
[0017] In a second aspect, the present invention provides the use of a triterpenoid compound represented by formula I or a pharmaceutically acceptable salt, ester, solvate or a combination thereof in the preparation of a cellular glucose uptake promoter and / or an α-glucosidase inhibitor:
[0018]
[0019] In a third aspect, the present invention provides a pharmaceutical composition comprising a triterpenoid compound represented by formula I or a pharmaceutically acceptable salt, ester, solvate thereof and a pharmaceutically acceptable excipient thereof, for use as a pharmaceutical preparation, wherein the drug is a hypoglycemic drug, a drug for treating or preventing diabetes:
[0020]
[0021] Preferably, the composition contains 0.001-99 wt % of the triterpenoid compound or a pharmaceutically acceptable salt, ester or solvate thereof, based on the total weight of the composition;
[0022] Preferably, the daily dosage of the triterpenoid compound is 0.01-100 mg / kg calculated based on body weight.
[0023] Preferably, the pharmaceutically acceptable excipients include any one or a combination of at least two of carriers, diluents, excipients, fillers, binders, wetting agents, disintegrants, emulsifiers, cosolvents, solubilizers, osmotic pressure regulators, surfactants, coating materials, colorants, pH regulators, antioxidants, antibacterial agents or buffers, such as a combination of binders and diluents, a combination of disintegrants and fillers, a combination of disintegrants, fillers and lubricants, etc. Other arbitrary combinations are not described here one by one.
[0024] Preferably, the pharmaceutical preparation is a tablet, capsule, injection, granule or oral liquid. The triterpenoid compound or its pharmaceutically acceptable salt, ester, solvate of the present invention can also be used in combination with other drugs to achieve better hypoglycemic effect.
[0025] In the present invention, the administration route of the drug can be selected according to actual needs, such as oral administration, sublingual administration, intravenous injection, intramuscular injection or subcutaneous injection. Oral administration or intravenous injection is preferred.
[0026] The present invention unexpectedly discovered that the triterpenoid compound represented by formula I or its pharmaceutically acceptable salt, ester, solvate can promote the uptake of glucose by fat cells and inhibit the activity of α-glucosidase, and can be used to lower blood sugar, that is, it can be used to prepare blood sugar-lowering drugs or functional foods, especially suitable for preparing drugs for preventing or treating diabetes, and can reduce high blood sugar in type 1 diabetes or type 2 diabetes. It has a dual-target blood sugar-lowering effect that clinical drugs that promote glucose uptake or α-glucosidase inhibitor drugs (such as acarbose) do not have. Therefore, it is expected that obtusalin can be used in clinical blood sugar-lowering, diabetes drugs or functional foods, and can be suitable for patients with type 1 and type 2 diabetes. Moreover, it is widely present in plants such as yellow cottonwood, has little toxic side effects, and has high safety. BRIEF DESCRIPTION OF THE DRAWINGS
[0027] Figure 1 :Effects of obtusalin on glucose uptake activity in adipocytes
[0028] Figure 2 :Effects of obtusalin on adipocyte viability Specific embodiments
[0029] The technical scheme of the present invention is further illustrated by specific examples below. Those skilled in the art should understand that the examples are only to help understand the present invention and should not be regarded as specific limitations of the present invention.
[0030] The process, conditions, reagents, experimental methods, etc. for implementing the present invention, except for the contents specifically mentioned below, are all common knowledge and common common sense in the art, and the present invention has no particular restrictions. The experimental methods without specifying specific conditions in the embodiments are usually carried out under conventional conditions or under conditions recommended by the manufacturer.
[0031] Unless otherwise specified, all technical terms and scientific terms used in this specification have the same meaning as those generally understood by those skilled in the art to which the present invention belongs. However, in case of any conflict, the present specification including the definitions shall prevail.
[0032] Among them, the compound obtusalin is a self-made sample from Zhang Yumei's laboratory in Xishuangbanna Tropical Botanical Garden, Chinese Academy of Sciences.
[0033] Drugs and reagents such as berberine, glucose, α-glucosidase, p-nitrophenyl-β-D-galactopyranoside, ascorbic acid and acarbose were purchased from Sigma and other companies.
[0034] Example 1
[0035] Preparation of obtusalin
[0036] 80kg of dried branches and leaves of the yellow cottonwood tree were sun-dried and crushed, then cold-extracted with industrial ethanol for 3 times (7, 3, 3 days), and methanol was recovered under reduced pressure to obtain 4.5kg of total extract. After the total extract was dissolved in hot water, it was extracted with petroleum ether, ethyl acetate and n-butanol respectively to obtain 225g of petroleum ether extract, 618g of ethyl acetate extract, 1410g of n-butanol extract and the aqueous phase.
[0037] The ethyl acetate portion was separated by silica gel column (200-300 mesh, 618 g) and eluted with chloroform-methanol (25:1, 12:1, 9:1, 5:1, 3:1, 1:1, 0:1) gradient to obtain 7 components (B1-B7). B2 was purified by repeated silica gel column chromatography, Sephadex LH-20 and recrystallization to obtain the compound obtusalin (4.25 g).
[0038] Mass spectrometry and nuclear magnetic resonance analysis were used to confirm the structure: the spectral data of obtusalin are as follows: EI-MS: 442[M] + (m / z).
[0039] 13 C-NMR (125MHz, CDCl3) δ: 38.8 (C-1), 27.2 (C-2), 79.0 (C-3), 38.0 (C-4), 55.2 (C-5), 18.3 (C-6), 32.8 ( C-7),40.0(C-8),47.7(C-9),36.9(C-10),23.3(C-11),125.0(C-12),138.7(C-13),42.0(C-14),23.4 (C-15),26.0(C-16),38.8(C-17),54.0(C-18),39.4(C-19),39.4(C-20),30.6(C-21),28.1(C-22),35 .2(C-23),16.8(C-24),15.6(C-25),69.9(C-26),15.7(C-27),23.3(C-28),21.4(C-29),17.4(C-30).
[0040] 1 H-NMR (500MHz, CDCl3) δ: 3.20 (1H, dd, J = 11.3, 4.7Hz, H-3), 5.13 (1H, t, J = 3 .6Hz,H-12),1.04(3H,s,H-22),0.96(3H,s,H-23),0.74(3H,s,H-24),3.44( 1H,d,J=10.9Hz,H-26a),3.15(1H,d,J=10.9Hz,H-26b),0.95(3H,s,H-25), 1.15(3H,s,H-27), 0.93(3H,d,J=6.2Hz,H-29), 0.80(3H,d,J=5.8Hz,H-30).
[0041] Example 2
[0042] Evaluation of the activity of obtusalin in promoting glucose uptake in adipocytes
[0043] Experimental principle:
[0044] Insulin regulates GLUT4 through specific signaling pathways such as the PI3K signaling pathway to transport glucose from outside the cell to the cell, allowing the cell to complete glucose uptake. Therefore, the cell's glucose uptake is one of the indicators that directly reflects insulin sensitivity. We test the activity of the test substance at a certain concentration on the cell. If the glucose uptake is increased, we will further conduct a dose-effect relationship study.
[0045] Experimental methods:
[0046] The experiment was divided into 3 groups, namely blank control, positive drug group (berberine), and compound group. First, the differentiated 3T3-L1 cells were inoculated into a 96-well plate and cultured overnight. After washing the 3T3-L1 cells in the 96-well plate once with PBS buffer, 200 μL of low-glucose culture medium containing different samples were added respectively. The blank control group was incubated with DMSO at the corresponding concentration, the positive control was incubated with 1ug / ml berberine, and the compound group was incubated with Obtusalin at a final concentration of 20μg / ml. Each sample was repeated 3 times. After incubation at 37°C for 48 hours, 10μl of cell culture medium was aspirated respectively, and the glucose concentration in the culture medium was determined by the glucose oxidase-peroxidase method, and the absorbance was determined at 405nm using a microplate reader. After the glucose uptake test, the CellTiter Cell viability was determined by water cell proliferation assay. 15 μL CellTiter Aqueous cell proliferation test reagent. After incubation at 37°C for 8 hours, the absorbance at 490 nm was measured using an enzyme marker to determine whether the compound was toxic to adipocytes. Glucose consumption rate and relative cell viability were calculated as follows:
[0047] Glucose consumption rate (%) = (A1-A2) / A1×100
[0048] Where A1 = absorbance of initial glucose, A2 = absorbance of blank control, positive control or sample group.
[0049] Relative cell viability (%) = A2 / A1×100
[0050] Where A1 = absorbance of blank control, A2 = absorbance of sample or positive control group.
[0051] The experimental results are shown in Figure 1 The results showed that obtusalin has a significant activity in promoting glucose uptake in adipocytes (the glucose uptake rate at a concentration of 20ug / ml was 52.16±1.09% (24 hours), 91.58±0.13%; the blank control was 44.60±0.46% (24 hours), 79.62±0.026% (48 hours); the positive drug berberine was 63.31±0.82% (24 hours), 95.00±0.26% (48 hours)), and had no obvious effect on the activity of adipocytes.
[0052] Example 3
[0053] Evaluation of the inhibitory activity of obtusalin on α-glucosidase
[0054] Experimental principle:
[0055] α-Glucosidase belongs to the class of oligosaccharide hydrolases. Its inhibitors competitively inhibit the action of glycosidases on the villi of the small intestinal epithelium to reduce the degradation of sugars, delay the digestion and absorption of sugars, and thus effectively reduce the peak blood sugar concentration after meals in diabetics, achieving the purpose of controlling blood sugar. α-Glucosidase inhibitors (such as acarbose, etc.) have become a class of oral hypoglycemic drugs widely used in clinical practice.
[0056] The activity screening of α-glucosidase inhibitors can be detected by the in vitro enzymatic reaction between the enzyme and its substrate p-nitrophenyl-β-D-pyranogalactoside (PNPG, a maltose analogue). After α-glucosidase is added to the substrate of the enzyme reaction, the substrate is decomposed into p-nitrophenol (PNP) and glucose by the enzyme. PNP is a colored substance with a maximum absorption at around 400nm. It can be measured by an enzyme reader, and the inhibitory activity of the sample is calculated based on the OD value.
[0057] Experimental methods:
[0058] Obrusalin sample solution: Prepare a 4 mmol / L solution with DMSO solution, and then dilute it to concentrations of 0.4, 0.2, 0.1, 0.05, and 0.025 mmol / L solutions.
[0059] Acarbose (positive control): Prepare a 2 mmol / L solution with DMSO solution, and then dilute to concentrations of 0.2, 0.1, 0.05, 0.025, and 0.0125 mmol / L solutions.
[0060] 10 μL of obtusalin sample solution or positive control solution with different concentrations, 50 μL of 0.1U / ml enzyme solution, 100 μL of 50mmol / L phosphate buffer solution with pH 7.0, and 40 μL of 5mmol / L substrate were sequentially added to a 96-well ELISA plate, mixed thoroughly, and two wells were set up for duplication. At the same time, a blank control without drug was set up (adding the same amount of DMSO solution). Incubate at 37°C for 50 minutes, and measure the OD value at 405nm with an ELISA reader (model Thermo Multiskan FC) to calculate the inhibition rate of α-glucosidase activity. The inhibition rate calculation formula is as follows:
[0061]
[0062] A0 is the OD value of the blank control group, and A1 is the OD value of the sample group.
[0063] Based on the inhibition rate, the IC was calculated according to the Reed & Muench method. 50 value.
[0064] The experimental results are shown in Table 1. The results show that obtusalin has a certain α-glucosidase inhibitory activity, and its IC 50 The value was 68.80±16.27μg / ml.
[0065] Table 1. Inhibitory activity of compound obtusalin on α-glucosidase
[0066]
[0067] Example 4
[0068] Tablets: 1 g of the compound obtusalin is mixed with 0.6 g of lactose and 0.5 g of starch, and the mixture is evenly moistened with water, sieved and dried, and then sieved again, and 0.1 g of magnesium stearate is added, mixed, and tableted into 20 tablets, with a tablet weight of 110 mg and a content of 50 mg / tablet.
[0069] Example 5
[0070] Capsules: 1 g of the compound obtusalin is mixed evenly with 0.5 g of lactose and 0.1 g of magnesium stearate, sieved, and mixed evenly. The resulting mixture is filled into 20 hard gelatin capsules, capsule weight: 80 mg, content: 50 mg / capsule.
[0071] Example 6
[0072] Oral ampoule: Add 1g of the compound obtusalin to conventional additives used to prepare oral solution and purified water, dilute to 0.1L, and aseptically fill into 20 ampoules, 5ml each, content: 50mg / bottle.
[0073] Example 7
[0074] Granules: Mix 1g of the compound obtusalin with 1g of lactose and 0.6g of starch, moisten them evenly with water, sieve the moistened mixture, dry it, sieve it again, and then make the mixture into granules and pack it into 20 bags, each bag weighing 130mg, with a content of 50mg / bag.
[0075] The above are only several embodiments of the present application, and are not intended to limit the present application in any form, that is, it does not mean that the present invention must rely on the above embodiments to be implemented. Those skilled in the art should understand that any improvement of the present invention, the equivalent replacement of the raw materials of the product of the present invention, the addition of auxiliary components, the selection of specific methods, etc., all fall within the protection scope and disclosure scope of the present invention. Within the scope of the technical concept of the present invention, a variety of simple variations can be made to the technical solution of the present invention, and these simple variations all belong to the protection scope of the present invention.
Claims
1. Use of the triterpenoid compound represented by formula I or its pharmaceutically acceptable salt in the preparation of hypoglycemic drugs: Formula Ⅰ.
2. Use of the triterpenoid compound represented by formula I or its pharmaceutically acceptable salt in the preparation of a drug for preventing and / or treating diabetes: Formula Ⅰ.
3. The use according to claim 1 or 2, characterized in that: The drug further comprises pharmaceutically acceptable excipients.
4. The use according to claim 3, characterized in that: The auxiliary materials include any one of carriers, fillers, adhesives, wetting agents, disintegrants, emulsifiers, cosolvents, solubilizers, osmotic pressure regulators, surfactants, coating materials, colorants, pH regulators, antioxidants, and antibacterial agents, or a combination of at least two of them.
5. The use as claimed in claim 3, characterized in that The drug dosage form is tablet, capsule, injection, granule or oral liquid.
